Unattributed Code Systems

• http://example.com/codelists/CL_ntprobnp_unit
• http://example.org
• http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
• http://snomed.info/sct
• http://spor.ema.europa.eu/v1/example-reason
• http://unstats.un.org/unsd/methods/m49/m49.htm
• https://fevir.net/sevco
• https://www.cas.org/support/documentation/chemical-substances
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
• https://www.nlm.nih.gov/mesh
• urn:ietf:bcp:47

Copyright Fragment

This fragment is available on index.html

Copyright and Registered Trademark Uses

• IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot2. Generated 2025-03-28 Links: Table of Contents | QA Report | Version History | CC0 | Propose a change ( src )
• hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )
• 14.622 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• : SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - JSON Representation ( src )
• : SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - TTL Representation ( src )
• : SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - XML Representation ( src )
• Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter: ( src )
• Citation SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• Codes for use with the Classifier drop-down menu for FEvIR(R): Recommendation Justification Builder. ( src )
• Computable Publishing® augments digital publishing with machine-interpretable forms. Computable Publishing® offers publishers of any type (commercial, nonprofit, academic, government) the ability to extend their published works with computable (machine-interpretable) forms of expression, and users of any type support in using computable data to enhance, improve and achieve desired outcomes. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Executable app], version 4.9.1. Contributors: Computable Publishing LLC [Author]. In: Fast Evidence Interoperability Resources (FEvIR) Platform. Published June 04, 2021. Revised October 09, 2023. Accessed November 25, 2023. Available at: https://fevir.net/ctgovconvert. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter converts ClinicalTrials.gov JSON to FEvIR Resources in FHIR® JSON. • Enter an NCT Identifier (NCTID) and click Submit. • FHIR Resources will be created for all Protocol and Results Section Data in the ClinicalTrials.gov record. • For related articles listed in MEDLINE, the Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter automates use of the Computable Publishing®: MEDLINE-to-FEvIR Converter. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter is one of the many Converter tools on the FEvIR Platform. • Converter Tools transform data between known structured forms and the FHIR standard form. • The FEvIR Platform provides access to an array of tools which enable creating and viewing scientific knowledge in standard-based, machine-interpretable units called Resources. ( src )
• Copyright © 2011 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved. ( src )
• Copyright © 2013 Elsevier Inc. All rights reserved. ( src )
• Copyright © 2013 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved. ( src )
• Copyright © 2015 Elsevier Inc. All rights reserved. ( src )
• Copyright © 2015 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2021 Massachusetts Medical Society. All rights reserved. ( src )
• Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ( src )
• Defines the content expected to be rendered in all representations of the artifact. The (c) symbol should NOT be included in this string. It is expected to be added by software when rendering the notation. Full details about licensing, restrictions, warrantees, etc. goes in the more general 'copyright' element. ( src )
• Example Citation: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• GLUCAGEN® and GLUCAGEN® Hypokit 1 mg (glucagon) Product Monograph. Mississauga, Ontario: Novo Nordisk Canada Inc.; 2014. http://www.paladin-labs.com/our_products/PM_GlucaGen_EN.pdf. Accessed 26 September 2015. ( src )
• Methods Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia. They were randomly assigned to receive supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care or standard of care medications alone. The primary endpoint was the proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization. This trial was registered with clinicaltrials.gov, NCT04401202. ( src )
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - JSON Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - TTL Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - XML Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2 ( src )
• The (c) symbol should NOT be included in this string. It will be added by software when rendering the notation. Full details about licensing, restrictions, warrantees, etc. goes in the more general 'copyright' element. ( src )
• The purpose of this research was to describe and interpret the positive body image experiences of women actively engaged in pole fitness. A total of seven women between the ages of 20 and 36 years participated in semistructured one-on-one interviews and follow-up interviews. Participant observation was also used to generate data. Data were analyzed using an interpretative phenomenological analysis approach, and the positive body image experiences of women are represented by five themes: (a) observation and exposure fostering body acceptance, (b) performance promoting self-confidence, (c) personal growth and sexual expression, (d) unconditional community support creates comfort, and (e) body appreciation through physical skill development. Findings suggest that women engaging in pole fitness may experience positive body image, and the words of participants provide insight into the components of pole fitness that may foster positive body image. Pole fitness may provide a unique exercise context whereby women can develop and maintain positive body image. ( src )
• The short copyright declaration (e.g. (c) '2015+ xyz organization' should be sent in the copyrightLabel element. ( src )
• This material contains content from LOINC. LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Show Usage * LOINC: Composition/256358, Composition/343018... Show 30 more , ConceptualCohortDefinition_At_least_2_risk_factors_for_stroke, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter, ConceptualCohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, ConceptualCohortDefinition_Severe_obesity, EGFR_45_59, Ethnic_Group, Group/267506, Group/279346, Group/279347, Group/282882, Group/297750, M11Report, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyEligibilityCriteria_Obese_patients_18_years_old and Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis ( src )
• This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html Show Usage * StatisticAttribute Estimate Type: AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis... Show 24 more , ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY and MeanDiffA1c2016metaAnalysis * StatisticCertaintyRating: ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study and ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study * EvidenceDirectness: Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19 and Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY * LibraryType: Library/179606, Library/179618... Show 4 more , Library/179632, SearchResults, SystematicReviewExcludedStudies and SystematicReviewIncludedStudies * List Empty Reasons: Composition/178426, Composition/179465... Show 12 more , Composition/179466, Composition/179467, Composition/179699, Composition/236538, Composition/256358, Composition/292951, Composition/307245, Composition/307248, Composition/312172, Composition/312203, Composition/318262 and Composition/343007 * Organization type: Computable_Publishing_LLC * PlanDefinitionType: PlanDefinition/179468, PlanDefinition/179554 and RecommendationPlan * ResearchStudyPhase: NCT03421379_FHIR_Transform_M11_IGBJ * ResearchStudyPrimaryPurposeType: NCT03421379_FHIR_Transform_M11_IGBJ * StatisticStatisticType: ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, AllCauseMortality2022metaAnalysis... Show 93 more , AllCauseMortalityControlGroup2022metaAnalysis, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313876, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313956, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313876, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313956, All_cause_mortality_from_MAGICapp_313876, All_cause_mortality_from_MAGICapp_313956, Body_weight_Comparator_Evidence_from_MAGICapp_109570, Body_weight_Comparator_Evidence_from_MAGICapp_109588, Body_weight_Intervention_Evidence_from_MAGICapp_109570, Body_weight_Intervention_Evidence_from_MAGICapp_109588, Body_weight_from_MAGICapp_109570, Body_weight_from_MAGICapp_109588, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_from_MAGICapp_313877, Cardiovascular_mortality_from_MAGICapp_313957, ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Diabetic_ketoacidosis_Comparator_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_Intervention_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_from_MAGICapp_313962, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_from_MAGICapp_313880, End_stage_kidney_disease_from_MAGICapp_313960, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY, Genital_infection_Comparator_Evidence_from_MAGICapp_313964, Genital_infection_Intervention_Evidence_from_MAGICapp_313964, Genital_infection_from_MAGICapp_313964, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_from_MAGICapp_109569, Health_related_quality_of_life_from_MAGICapp_109587, Heart_failure_Comparator_Evidence_from_MAGICapp_313881, Heart_failure_Comparator_Evidence_from_MAGICapp_313961, Heart_failure_Intervention_Evidence_from_MAGICapp_313881, Heart_failure_Intervention_Evidence_from_MAGICapp_313961, Heart_failure_from_MAGICapp_313881, Heart_failure_from_MAGICapp_313961, MeanDiffA1c2016metaAnalysis, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_from_MAGICapp_313878, Nonfatal_myocardial_infarction_from_MAGICapp_313958, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313959, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313959, Nonfatal_stroke_from_MAGICapp_313879, Nonfatal_stroke_from_MAGICapp_313959, ResearchStudyOutcomeMeasure, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_from_MAGICapp_313882, Serious_hyperglycaemia_from_MAGICapp_313963, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_from_MAGICapp_313883 and Severe_gastrointestinal_events_from_MAGICapp_313965 * StatisticSynthesisType: AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis... Show 35 more , ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Myocardial_infarction_or_stroke_without_bariatric_surgery_Control_Group_in_Swedish_Obese_Subjects_SOS_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Death_or_Major_Traumatic_Injury_on_Impact_comparing_intervention_vs_comparator, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, MeanDiffA1c2016metaAnalysis, NMA_Diabetes and SingleStudyEvidence * UsageContextType: Citation/5296, Citation/7636, Citation/7638 and Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19 * identifierType: ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Adults_with_type_2_diabetes... Show 530 more , Adults_with_type_2_diabetes_with_moderate_CV_risk, Age, Age_with_comparator, Age_with_intervention, Aircraft_Type_with_comparator, Aircraft_Type_with_intervention, AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis, All_cause_mortality313876, All_cause_mortality313956, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313876, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313956, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313876, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313956, All_cause_mortality_from_MAGICapp_313876, All_cause_mortality_from_MAGICapp_313956, Altitude, Altitude_comparing_intervention_vs_comparator, Altitude_for_enrolled_group, Altitude_for_screened_group, Altitude_with_comparator, Altitude_with_intervention, An_example_of_OutcomeDefinition_Profile_which_is_a_conceptual_group_used_to_provided_a_definition_for_an_EvidenceVariable, Analyte_type_of_the_sample, ArtifactAssessment/104064, ArtifactAssessment/104192, ArtifactAssessment/104193, ArtifactAssessment/104194, ArtifactAssessment/104195, ArtifactAssessment/104196, ArtifactAssessment/171898, ArtifactAssessment/179448, ArtifactAssessment/179469, ArtifactAssessment/179515, ArtifactAssessment/179692, ArtifactAssessment/179693, ArtifactAssessment/179694, ArtifactAssessment/179698, ArtifactAssessment/179700, ArtifactAssessment/181452, ArtifactAssessment/307449, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17, Bariatric_Surgery_RYGB_VSG_LAGB_BPD, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group, Birthdate, Body_site_where_sample_was_collected, Body_weight109570, Body_weight109588, Body_weight_Comparator_Evidence_from_MAGICapp_109570, Body_weight_Comparator_Evidence_from_MAGICapp_109588, Body_weight_Intervention_Evidence_from_MAGICapp_109570, Body_weight_Intervention_Evidence_from_MAGICapp_109588, Body_weight_from_MAGICapp_109570, Body_weight_from_MAGICapp_109588, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, COVID_19PneumoniaHospitalizedAdult, CTIS2024_516402_32_00_Eligibility_Criteria, CTIS2024_516402_32_00_Primary_Outcome_1, CTIS2024_516402_32_00_Secondary_Outcome_1, CTIS2024_516402_32_00_Secondary_Outcome_2, CTIS2024_516402_32_00_Secondary_Outcome_3, CTIS2024_516402_32_00_Secondary_Outcome_4, CTIS2024_516402_32_00_Secondary_Outcome_5, CTIS2024_516402_32_00_Secondary_Outcome_6, CTIS2024_516402_32_00_Secondary_Outcome_7, CTIS2024_516402_32_00_Secondary_Outcome_8, CTIS_2024_516402_32_00_FHIR_Transform, Cardiovascular_mortality313877, Cardiovascular_mortality313957, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_from_MAGICapp_313877, Cardiovascular_mortality_from_MAGICapp_313957, Case_id, Citation/104116, Citation/121719, Citation/139859, Citation/139860, Citation/153881, Citation/179558, Citation/179559, Citation/179560, Citation/179561, Citation/179594, Citation/179595, Citation/179596, Citation/179597, Citation/179598, Citation/179599, Citation/179600, Citation/179601, Citation/179602, Citation/179603, Citation/179604, Citation/179605, Citation/179613, Citation/179615, Citation/179616, Citation/179617, Citation/179621, Citation/179622, Citation/179623, Citation/179624, Citation/179625, Citation/179626, Citation/179627, Citation/179628, Citation/179629, Citation/179630, Citation/179631, Citation/179637, Citation/247416, Citation/264329, Citation/267246, Citation/267247, Citation/267496, Citation/267497, Citation/267498, Citation/267499, Citation/267500, Citation/267501, Citation/29812, Citation/306957, Citation/32137, Citation/33089, Citation/33399, Citation/33400, Citation/5296, Citation/58, Citation/7636, Citation/7638, CodeSystemRecommendationJustification, ComparativeBaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeBaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort, ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial, ComparatorDefinition_Obese_patients_18_years_old_without_bariatric_surgery, ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Myocardial_infarction_or_stroke_without_bariatric_surgery_Control_Group_in_Swedish_Obese_Subjects_SOS_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Composition/104215, Composition/104383, Composition/178426, Composition/179465, Composition/179466, Composition/179467, Composition/179699, Composition/236537, Composition/236538, Composition/236951, Composition/256358, Composition/292951, Composition/307245, Composition/307248, Composition/312172, Composition/312203, Composition/318262, Composition/342828, Composition/343007, Composition/343018, Computable_Publishing_LLC, ConceptualCohortDefinition_At_least_2_risk_factors_for_stroke, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years, ConceptualCohortDefinition_Cardiovascular_event, ConceptualCohortDefinition_Heart_failure_based_on_Phenotypes, ConceptualCohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration, ConceptualCohortDefinition_Nonfatal_myocardial_infarction, ConceptualCohortDefinition_Nonfatal_stroke, ConceptualCohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter, ConceptualCohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, ConceptualCohortDefinition_Severe_obesity, ConceptualComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, ConceptualComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis, ConceptualExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin, Condition_code, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Cs_ebm_ig, Death_or_Major_Traumatic_Injury_30_days_after_Impact_comparing_intervention_vs_comparator, Death_or_Major_Traumatic_Injury_30_days_after_Impact_with_comparator, Death_or_Major_Traumatic_Injury_30_days_after_Impact_with_intervention, Death_or_Major_Traumatic_Injury_on_Impact_comparing_intervention_vs_comparator, Declined_randomization_in_PARACHUTE_Study, Deemed_unsuitable_by_investigator_in_PARACHUTE_Trial, DeviceDefinition/179899, Diabetic_ketoacidosis313962, Diabetic_ketoacidosis_Comparator_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_Intervention_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_from_MAGICapp_313962, DichotomousIntendedOutcome_Death_or_Major_Traumatic_Injury_within_30_days, EBMImplementationGuideProfile_Value_Set, EGFR_45_59, End_stage_kidney_disease313880, End_stage_kidney_disease313960, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_from_MAGICapp_313880, End_stage_kidney_disease_from_MAGICapp_313960, Ethnic_Group, Ethnic_Group_with_comparator, Ethnic_Group_with_intervention, EvidenceReportSectionCode_Value_Set, EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Example_Variable_Definition_for_EBMonFHIR_IG, Example_variable_definition_for_the_EBMonFHIR_IG, Excluded_from_PARACHUTE_Study, ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort, ExposureVariable_Age_as_continuous_variable, ExposureVariable_Body_Mass_Index_as_continuous_variable, Family_History_of_Parachute_Use, Family_History_of_Parachute_Use_with_comparator, Family_History_of_Parachute_Use_with_intervention, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY, Frequent_Flier, Frequent_Flier_with_comparator, Frequent_Flier_with_intervention, GLU_J, Gender, Genital_infection313964, Genital_infection_Comparator_Evidence_from_MAGICapp_313964, Genital_infection_Intervention_Evidence_from_MAGICapp_313964, Genital_infection_from_MAGICapp_313964, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85390_I_85789, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85394_C_85798, Group/236534, Group/236535, Group/236948, Group/236949, Group/264323, Group/264328, Group/265092, Group/265093, Group/267506, Group/270503, Group/279340, Group/279346, Group/279347, Group/282882, Group/282891, Group/282899, Group/292955, Group/297486, Group/297487, Group/297488, Group/297489, Group/297750, Group/306655, Group/306657, Group/306658, Group/306659, Group/306660, Group/307440, Group/33395, GroupAssignment_Bariatric_Surgery_vs_no_bariatric_surgery, GroupAssignment_ExposureDefinition_Bariatric_Surgery_RYGB_VSG_LAGB_BPD_vs_ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, GroupAssignment_ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort_vs_ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, GroupAssignment_GLP_1_RA_vs_Standard_care, GroupAssignment_Jumping_from_aircraft_with_parachute_vs_Jumping_from_aircraft_with_empty_backpack, GroupAssignment_Non_Participants_vs_Enrolled_Participants, GroupAssignment_Roux_en_Y_gastric_bypass_or_Biliopancreatic_Diversion_vs_medical_treatment, GroupAssignment_Roux_en_Y_gastric_bypass_surgery_vs_Lifestyle_intensive_medical_management_intervention_alone, GroupAssignment_Roux_en_Y_gastric_bypass_vs_medical_treatment, GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA, GroupAssignment_high_dose_xanomeline_vs_low_dose_xanomeline_vs_placebo, Health_Survey_Score_Mental_Health_Subscore, Health_Survey_Score_Mental_Health_Subscore_comparing_intervention_vs_comparator, Health_Survey_Score_Mental_Health_Subscore_with_comparator, Health_Survey_Score_Mental_Health_Subscore_with_intervention, Health_Survey_Score_Physical_Health_Subscore, Health_Survey_Score_Physical_Health_Subscore_comparing_intervention_vs_comparator, Health_Survey_Score_Physical_Health_Subscore_with_comparator, Health_Survey_Score_Physical_Health_Subscore_with_intervention, Health_Survey_Score_Total, Health_Survey_Score_Total_comparing_intervention_vs_comparator, Health_Survey_Score_Total_with_comparator, Health_Survey_Score_Total_with_intervention, Health_related_quality_of_life109569, Health_related_quality_of_life109587, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_from_MAGICapp_109569, Health_related_quality_of_life_from_MAGICapp_109587, Heart_failure313881, Heart_failure313961, Heart_failure_Comparator_Evidence_from_MAGICapp_313881, Heart_failure_Comparator_Evidence_from_MAGICapp_313961, Heart_failure_Intervention_Evidence_from_MAGICapp_313881, Heart_failure_Intervention_Evidence_from_MAGICapp_313961, Heart_failure_from_MAGICapp_313881, Heart_failure_from_MAGICapp_313961, Height_with_comparator, Height_with_intervention, History_of_Acrophobia, History_of_Acrophobia_with_comparator, History_of_Acrophobia_with_intervention, History_of_Broken_Bones, History_of_Broken_Bones_with_comparator, History_of_Broken_Bones_with_intervention, History_of_Parachute_Use, History_of_Parachute_Use_with_comparator, History_of_Parachute_Use_with_intervention, ICD10GM_Terminale_Codes, IV_remdesivir_200_mg_then_100_mg_day_for_9_days, Injury_Severity_Score_30_days_after_Impact_comparing_intervention_vs_comparator, Injury_Severity_Score_30_days_after_Impact_with_comparator, Injury_Severity_Score_30_days_after_Impact_with_intervention, Injury_Severity_Score_on_Impact_comparing_intervention_vs_comparator, Injury_Severity_Score_on_Impact_with_comparator, Injury_Severity_Score_on_Impact_with_intervention, International_vs_Domestic_Flight, International_vs_Domestic_Flight_with_comparator, International_vs_Domestic_Flight_with_intervention, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, Investigator, Investigator_by_treatment_interaction_for_ADAS_Cog11_ANCOVA, LBDGLUSI, LBXGLU, Library/179606, Library/179618, Library/179632, List/179470, List/179579, List/179585, List/179800, List/307202, List/307246, List/307247, List/312201, List/312205, MeanDiffA1c2016metaAnalysis, Median_Age_SD, MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs, Mortality14Day, NCT03421379_FHIR_Transform_M11_IGBJ, NMA_Diabetes, NTproBNP, NetEffectContribution_Additional_GI_surgical_procedure_for_Example_for_GIN_2022, NetEffectContribution_All_cause_mortality_for_Example_for_GIN_2022, NetEffectContribution_New_onset_depression_for_Example_for_GIN_2022, NetEffectContribution_Nonfatal_myocardial_infarction_or_stroke_for_Example_for_GIN_2022, NetEffectContribution_Remission_of_diabetes_for_Example_for_GIN_2022, NetEffectContribution_Treatment_with_opioids_for_Example_for_GIN_2022, NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022, NetEffectEstimate_Bariatric_Surgery_Example_for_GIN_2022, Nonfatal_myocardial_infarction313878, Nonfatal_myocardial_infarction313958, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_from_MAGICapp_313878, Nonfatal_myocardial_infarction_from_MAGICapp_313958, Nonfatal_stroke313879, Nonfatal_stroke313959, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313959, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313959, Nonfatal_stroke_from_MAGICapp_313879, Nonfatal_stroke_from_MAGICapp_313959, Ntprobnp_comparator, Ntprobnp_date, Ntprobnp_time, Ntprobnp_unit, Organ_support_free_days, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_Diabetes_in_remission, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, OutcomeDefinition_New_onset_depression, OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke, OutcomeVariable_Additional_GI_surgical_procedure, OutcomeVariable_All_cause_mortality, OutcomeVariable_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control_at_5_years, OutcomeVariable_HbA1c_at_12_months, OutcomeVariable_HbA1c_at_24_months, OutcomeVariable_HbA1c_at_36_months, OutcomeVariable_HbA1c_at_60_months, OutcomeVariable_HbA1c_at_6_months, OutcomeVariable_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, OutcomeVariable_New_onset_depression, OutcomeVariable_Nonfatal_myocardial_infarction_or_stroke, OutcomeVariable_Remission_of_diabetes, OutcomeVariable_Treatment_with_opioids, Outcome_Death_or_Major_Traumatic_Injury_30_days_after_Impact, Outcome_Death_or_Major_Traumatic_Injury_on_Impact, Outcome_Injury_Severity_Score_30_days_after_Impact, Outcome_Injury_Severity_Score_on_Impact, PARACHUTE_Trial_Participants_available_for_randomization, PARACHUTE_Trial_Participants_deemed_unsuitable_by_investigator, PARACHUTE_Trial_Participants_randomized_into_groups, PARACHUTE_Trial_Participants_randomized_into_groups_for_screened_group, PARACHUTE_Trial_Participants_randomized_into_groups_with_comparator, PARACHUTE_Trial_Participants_randomized_into_groups_with_intervention, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up_with_comparator, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up_with_intervention, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up_with_comparator, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up_with_intervention, PARACHUTE_Trial_Participants_that_declined_randomization, PARACHUTE_Trial_Participants_with_no_contact_at_30_days, PARACHUTE_Trial_Participants_with_no_contact_at_30_days_with_comparator, PARACHUTE_Trial_Participants_with_no_contact_at_30_days_with_intervention, Parachute_vs_Empty_Backpack_in_PARACHUTE_Trial, ParticipantFlowEvidence_2018_Norwegian_Cohort_Excluded_from_Analysis, ParticipantFlowMeasure_Dropout_due_to_stopping_intervention, ParticipantFlowMeasure_Exclusion_from_analysis, ParticipantFlowMeasure_Inclusion_in_analysis, ParticipantFlow_2018_Norwegian_Cohort_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Medical_Group_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Surgical_Group_Included_in_Analysis, Participants_Excluded_from_PARACHUTE_Study, Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill, Patient_id, Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill, Placebo, PlanDefinition/179468, PlanDefinition/179554, PlanDefinition/181450, Randomized_into_groups_for_PARACHUTE_Trial, Rate_of_Death_or_Major_Traumatic_Injury_on_Impact_with_comparator, Rate_of_Death_or_Major_Traumatic_Injury_on_Impact_with_intervention, Remdesivir, Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days, Risk_of_bias_type, SEQN, Sample_ID, SearchStrategyCharacteristicCode_Value_Set, SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review, SearchStrategy_PubMed_search_for_Wonder_Woman, Self_reported_race, Self_reported_sex, Serious_hyperglycaemia313882, Serious_hyperglycaemia313963, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_from_MAGICapp_313882, Serious_hyperglycaemia_from_MAGICapp_313963, Severe_gastrointestinal_events313883, Severe_gastrointestinal_events313965, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_from_MAGICapp_313883, Severe_gastrointestinal_events_from_MAGICapp_313965, Severely_Obese_Adults_2018_Norwegian_Cohort, Sex, Sex_with_comparator, Sex_with_intervention, Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798, Source_of_sample, Standard_care85390_C_85789, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyEligibilityCriteria_Obese_patients_18_years_old, StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group, StudyGroup_DIBASY_Trial_Enrollment_Group, Subject_ID, Subject_age_at_diagnosis, SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer, Technology_employed_on_the_sample, The_tumor_status_of_the_sample, Therapeutic_dose_anticoagulation_with_heparin_vs_Usual_care_pharmacologic_thromboprophylaxis, Time_to_integration_of_results_in_a_recommendation, Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, Velocity, Velocity_comparing_intervention_vs_comparator, Velocity_for_enrolled_group, Velocity_for_non_participant_group, Velocity_with_comparator, Velocity_with_intervention, WTSAF2YR, Weight, Weight_with_comparator, Weight_with_intervention and Year_2018_Norwegian_Cohort_Study * EvidenceVariableRole: Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY ( src )
• author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter: ( src )
• author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter: , Joanne Dehnbostel: ( src )
• author: Computable Publishing®: MAGIC-to-FEvIR Converter: ( src )
• author: Computable Publishing®: MEDLINE-to-FEvIR Converter: ( src )
• title: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. ( src )
• © 2020 by the American Diabetes Association. ( src )
• © 2023 Computable Publishing LLC, Patent Pending. ( src )
• © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. ( src )
• © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ( src )
• © The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. ( src )

External References

Internal Images